Regeneron Announces Investor Conference Presentations
Regeneron Pharmaceuticals (NASDAQ: REGN) has announced its upcoming participation in two major investor conferences. The company will present at the Jefferies London Healthcare Conference on November 19, 2024, at 11:00 a.m. BST (6:00 a.m. ET), and at the Piper Sandler 36th Annual Healthcare Conference on December 5, 2024, at 9:30 a.m. ET.
Both presentations will be accessible via webcast through Regeneron's investor relations website. Recordings and transcripts will remain available for a minimum of 30 days after the events.
Regeneron Pharmaceuticals (NASDAQ: REGN) ha annunciato la sua prossima partecipazione a due importanti conferenze per investitori. L'azienda si presenterà alla Jefferies London Healthcare Conference il 19 novembre 2024, alle 11:00 BST (6:00 ET), e alla Piper Sandler 36th Annual Healthcare Conference il 5 dicembre 2024, alle 9:30 ET.
Entrambe le presentazioni saranno accessibili tramite webcast attraverso il sito web delle relazioni con gli investitori di Regeneron. Le registrazioni e le trascrizioni rimarranno disponibili per un minimo di 30 giorni dopo gli eventi.
Regeneron Pharmaceuticals (NASDAQ: REGN) ha anunciado su próxima participación en dos importantes conferencias para inversores. La empresa se presentará en la Jefferies London Healthcare Conference el 19 de noviembre de 2024, a las 11:00 a.m. BST (6:00 a.m. ET), y en la Piper Sandler 36th Annual Healthcare Conference el 5 de diciembre de 2024, a las 9:30 a.m. ET.
Ambas presentaciones estarán disponibles a través de un webcast en el sitio web de relaciones con inversores de Regeneron. Las grabaciones y transcripciones estarán disponibles durante un mínimo de 30 días después de los eventos.
리제너론 제약 (NASDAQ: REGN)은 두 가지 주요 투자자 회의에 참가할 것이라고 발표했습니다. 이 회사는 2024년 11월 19일 BST 시간으로 오전 11:00 (ET 시간으로 오전 6:00)에 제프리스 런던 헬스케어 회의에서 발표할 예정이며, 2024년 12월 5일 ET 시간으로 오전 9:30에 파이퍼 샌들러 제36회 연례 헬스케어 회의에서 발표할 예정입니다.
두 발표는 리제너론의 투자자 관계 웹사이트를 통해 웹캐스트로 접근할 수 있습니다. 이벤트 후 최소 30일 동안 녹화 및 전사가 제공됩니다.
Regeneron Pharmaceuticals (NASDAQ: REGN) a annoncé sa prochaine participation à deux grandes conférences pour investisseurs. L'entreprise présentera à la Jefferies London Healthcare Conference le 19 novembre 2024, à 11h00 BST (6h00 ET), et à la Piper Sandler 36th Annual Healthcare Conference le 5 décembre 2024, à 9h30 ET.
Les deux présentations seront accessibles par webcast via le site des relations investisseurs de Regeneron. Les enregistrements et les transcriptions resteront disponibles pendant au moins 30 jours après les événements.
Regeneron Pharmaceuticals (NASDAQ: REGN) hat seine bevorstehende Teilnahme an zwei bedeutenden Investorenkonferenzen angekündigt. Das Unternehmen wird am 19. November 2024 um 11:00 Uhr BST (6:00 Uhr ET) auf der Jefferies London Healthcare Conference präsentieren und am 5. Dezember 2024 um 9:30 Uhr ET auf der Piper Sandler 36th Annual Healthcare Conference.
Beide Präsentationen werden über einen Webcast über die Investor-Relations-Website von Regeneron zugänglich sein. Aufzeichnungen und Transkripte werden mindestens 30 Tage nach den Veranstaltungen verfügbar sein.
- None.
- None.
TARRYTOWN, N.Y., Nov. 11, 2024 (GLOBE NEWSWIRE) -- Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) will webcast management participation as follows:
• Jefferies London Healthcare Conference at 11:00 a.m. BST (6:00 a.m. ET) on
Tuesday, November 19, 2024
• Piper Sandler 36th Annual Healthcare Conference at 9:30 a.m. ET on Thursday,
December 5, 2024
The sessions may be accessed from the "Investors & Media" page of Regeneron's website at https://investor.regeneron.com/events-and-presentations. Replays and transcripts of the webcasts will be archived on the Company's website for at least 30 days.
About Regeneron
Regeneron (NASDAQ: REGN) is a leading biotechnology company that invents, develops and commercializes life-transforming medicines for people with serious diseases. Founded and led by physician-scientists, our unique ability to repeatedly and consistently translate science into medicine has led to numerous approved treatments and product candidates in development, most of which were homegrown in our laboratories. Our medicines and pipeline are designed to help patients with eye diseases, allergic and inflammatory diseases, cancer, cardiovascular and metabolic diseases, neurological diseases, hematologic conditions, infectious diseases, and rare diseases.
Regeneron pushes the boundaries of scientific discovery and accelerates drug development using our proprietary technologies, such as VelociSuite®, which produces optimized fully human antibodies and new classes of bispecific antibodies. We are shaping the next frontier of medicine with data-powered insights from the Regeneron Genetics Center® and pioneering genetic medicine platforms, enabling us to identify innovative targets and complementary approaches to potentially treat or cure diseases.
For more information, please visit www.Regeneron.com or follow Regeneron on LinkedIn, Instagram, Facebook or X.
Contact Information:
Investor Relations
Ryan Crowe
914.847.8790
ryan.crowe@regeneron.com
FAQ
When is Regeneron (REGN) presenting at the Jefferies London Healthcare Conference 2024?
What time is Regeneron's (REGN) presentation at the Piper Sandler Healthcare Conference 2024?
How long will Regeneron's (REGN) conference webcasts be available for replay?